Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 20;15:1354297. doi: 10.3389/fimmu.2024.1354297

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Masad, Idriss, Mohamed, Al-Sbiei, Bashir, Al-Marzooq, Altahrawi, Fernandez-Cabezudo and Al-Ramadi

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Enhancement in tumor immunogenicity as a consequence of MH administration. (A–C) Representative flow plots (A) and quantification of the percentage of MHC-I^lo (B) and MHC-I^hi (C) (gated on CD45^- cells) in SC-treated and MH-treated mice. (D) Representative overlay histograms showing MHC-I expression on CD45^- cells of SC-treated and MH-treated mice. The grey histogram indicates staining with FMO control (E) Median fluorescence intensity of MHC-I⁺ CD45^- cells in SC-treated and MH-treated groups. The values for individual mice and mean ± SEM are shown (SC: n=3, MH: n=5), obtained from 1 experiment. Asterisks denote statistically significant differences between MH-treated and SC-treated groups. p values were calculated using the unpaired Student’s t-test, * (p ≤ 0.05), ** (p ≤ 0.01), and ns (no statistical significance, p > 0.05).